IFN-α2a enhances macrophage-medicated depletion of Sézary cells by anti-CCR4 antibodies. (A) Gating strategy to identify CD80^high and CD80^low CD14⁺CD11b⁺ cells in the peripheral blood of 14 patients with SS. (B) Percentage of CD80^high and CD80^low among CD14⁺CD11b⁺ cells in the peripheral blood of 14 patients with SS. (C) Percentage of CD163^high and CD163^low among CD14⁺CD11b⁺ cells in the peripheral blood of 14 patients with SS. (D) Overall survival of 14 patients with SS based on the level of CD163 expression on CD14⁺CD11b⁺ cells in the peripheral blood. (E) Hierarchical clustering analysis by the 2-way joining of mean fluorescent intensity (MFI) of various differentiation markers on the Mф after exposure to sera of patients with SS in comparison with healthy sera. (F) Cytokine profile of sera of patients with SS and supernatant obtained 7 days after coincubation of healthy Mф with sera from patients with SS. ∗P < .05. (G) Phagocytosis of Sézary cells vs normal T cells in the presence or absence of anti-CCR4 antibody. ∗∗∗P < .001; ∗∗∗∗P < .0001 by analysis of variance (ANOVA) with Šidák multiple pairwise comparisons. (H) Phagocytosis of Sézary cells vs normal T cells after coculture in anti-CCR4 antibody with or without IFN-α2a. ns, nonsignificant; ∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001 by analysis of ANOVA with Šidák multiple pairwise comparisons. (I-J) Flow cytometry MFI of (I) CD80 and (J) CD86 on macrophages after coculture with Sézary cells in anti-CCR4 antibody with or without IFN-α2a supplementation. ns, nonsignificant; ∗P < .05 by ratio paired t test.